These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 33514682)

  • 1. Evaluation of Reduced-Dose Decitabine and Azacitidine for Treating Myelodysplastic Syndromes: A Retrospective Study.
    Hu N; Qin T; Du X; Wang B; Wang X; Xu Z; Pan L; Qu S; Xiao Z
    Med Sci Monit; 2021 Jan; 27():e928454. PubMed ID: 33514682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of hypomethylating agents and associated care in patients with myelodysplastic syndromes: a claims database study.
    Hatoum HT; Lin SJ; Buchner D; Kim E
    Curr Med Res Opin; 2011 Jun; 27(6):1255-62. PubMed ID: 21554144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hematologic outcomes of myelodysplastic syndromes treatment with hypomethylating agents in community practice.
    Bordoni RE; Feinberg BA; Gilmore JW; Haislip S; Jackson JH; Farrelly E; Kim E; Buchner D
    Clin Lymphoma Myeloma Leuk; 2011 Aug; 11(4):350-4. PubMed ID: 21816373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Azacitidine and Decitabine in Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Network Meta-analysis.
    Liu W; Zhou Z; Chen L; Wang X
    Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):e530-e544. PubMed ID: 33716056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN.
    Jabbour E; Short NJ; Montalban-Bravo G; Huang X; Bueso-Ramos C; Qiao W; Yang H; Zhao C; Kadia T; Borthakur G; Pemmaraju N; Sasaki K; Estrov Z; Cortes J; Ravandi F; Alvarado Y; Komrokji R; Sekeres MA; Steensma DP; DeZern A; Roboz G; Kantarjian H; Garcia-Manero G
    Blood; 2017 Sep; 130(13):1514-1522. PubMed ID: 28774880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Long-term hypomethylating agents in patients with myelodysplastic syndromes: a multi-center retrospective study].
    Liu XZ; Zhou SJ; Huang J; Zhao CF; Jiang LX; Zhang YD; Mei C; Ma LY; Zhou XP; Shao YP; Wu GQ; Xiao XB; Yao RX; Du XH; Hu TL; Qian SX; Li Y; Yan XF; Huang L; Wang ML; Fu JP; Shou LH; Jiang WH; Jin WM; Li LJ; Le J; Luo WJ; Zhang Y; Zhou XJ; Zhang H; Lang XH; Zhou M; Jin J; Jiang HF; Zhang J; Ouyang GF; Tong HY
    Zhonghua Xue Ye Xue Za Zhi; 2024 Aug; 45(8):738-747. PubMed ID: 39307720
    [No Abstract]   [Full Text] [Related]  

  • 7. Differential response to hypomethylating agents based on sex: a report on behalf of the MDS Clinical Research Consortium (MDS CRC).
    DeZern AE; Zeidan AM; Barnard J; Hand W; Al Ali N; Brown F; Zimmerman C; Roboz GJ; Garcia-Manero G; Steensma DP; Komrokji RS; Sekeres MA;
    Leuk Lymphoma; 2017 Jun; 58(6):1325-1331. PubMed ID: 27774847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison between 5-day decitabine and 7-day azacitidine for lower-risk myelodysplastic syndromes with poor prognostic features: a retrospective multicentre cohort study.
    Lee BH; Kang KW; Jeon MJ; Yu ES; Kim DS; Choi H; Lee SR; Sung HJ; Kim BS; Choi CW; Park Y
    Sci Rep; 2020 Jan; 10(1):39. PubMed ID: 31913293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.
    Schroeder T; Rautenberg C; Krüger W; Platzbecker U; Bug G; Steinmann J; Klein S; Hopfer O; Nachtkamp K; Kondakci M; Geyh S; Haas R; Germing U; Bornhäuser M; Kobbe G
    Ann Hematol; 2018 Feb; 97(2):335-342. PubMed ID: 29151133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison Between Decitabine and Azacitidine for Patients With Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndrome: A Systematic Review and Network Meta-Analysis.
    Ma J; Ge Z
    Front Pharmacol; 2021; 12():701690. PubMed ID: 34483903
    [No Abstract]   [Full Text] [Related]  

  • 11. High-dose regimens of hypomethylating agents promote transfusion independence in IPSS lower-risk myelodysplastic syndromes: a meta-analysis of prospective studies.
    Wan Z; Han B
    Aging (Albany NY); 2021 Mar; 13(8):11120-11134. PubMed ID: 33818418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated fetal haemoglobin is a predictor of better outcome in MDS/AML patients receiving 5-aza-2'-deoxycytidine (Decitabine).
    Lübbert M; Ihorst G; Sander PN; Bogatyreva L; Becker H; Wijermans PW; Suciu S; Bissé E; Claus R
    Br J Haematol; 2017 Feb; 176(4):609-617. PubMed ID: 27905102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing DNA hypomethylating therapy in acute myeloid leukemia and myelodysplastic syndromes.
    Straube J; Lane SW; Vu T
    Bioessays; 2021 Oct; 43(10):e2100125. PubMed ID: 34463368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of 7-day azacitidine and 5-day decitabine for treating myelodysplastic syndrome.
    Lee JH; Choi Y; Kim SD; Kim DY; Lee JH; Lee KH; Lee SM; Cho SH; Lee WS; Joo YD
    Ann Hematol; 2013 Jul; 92(7):889-97. PubMed ID: 23420388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients.
    Wijermans P; Lübbert M; Verhoef G; Bosly A; Ravoet C; Andre M; Ferrant A
    J Clin Oncol; 2000 Mar; 18(5):956-62. PubMed ID: 10694544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Decitabine treatment in myelodysplastic syndromes--results of a compassionate patient program in Israel].
    Klepfish A; Silbershatz I; Lugassy G; Shimoni A; Mittelman M
    Harefuah; 2013 Oct; 152(10):591-4, 624. PubMed ID: 24450031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients.
    Coston T; Pophali P; Vallapureddy R; Lasho TL; Finke CM; Ketterling RP; Carr R; Binder M; Mangaonkar AA; Gangat N; Al-Kali A; Litzow M; Zblewski D; Pardanani A; Tefferi A; Patnaik MM
    Am J Hematol; 2019 Jul; 94(7):767-779. PubMed ID: 30964202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes.
    Lyons RM; Cosgriff TM; Modi SS; Gersh RH; Hainsworth JD; Cohn AL; McIntyre HJ; Fernando IJ; Backstrom JT; Beach CL
    J Clin Oncol; 2009 Apr; 27(11):1850-6. PubMed ID: 19255328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial.
    Steensma DP; Baer MR; Slack JL; Buckstein R; Godley LA; Garcia-Manero G; Albitar M; Larsen JS; Arora S; Cullen MT; Kantarjian H
    J Clin Oncol; 2009 Aug; 27(23):3842-8. PubMed ID: 19528372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes.
    Zeidan AM; Davidoff AJ; Long JB; Hu X; Wang R; Ma X; Gross CP; Abel GA; Huntington SF; Podoltsev NA; Hajime U; Prebet T; Gore SD
    Br J Haematol; 2016 Dec; 175(5):829-840. PubMed ID: 27650975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.